Galapagos and Servier initiated their strategic alliance to develop new OA therapies in July 2010. The alliance builds on novel OA drug targets discovered by Galapagos through its proprietary platform. Galapagos discovered and developed new small molecule candidate drugs against these targets. In July 2017, Servier inlicensed the ex-US rights to GLPG1972 and will be responsible for the further clinical development, registration and commercialization. For any marketed products, Galapagos retains exclusive U.S. commercialization rights. Under the terms of the agreement, Galapagos is also eligible to receive discovery, development, regulatory and other milestone payments plus royalties upon commercialization of products outside the US.
In June 2018 Servier and Galapagos announced the start of the global ROCCELLA Phase 2 trial with GLPG1972 in osteoarthritis patients.
The Aggrecanase OA Research Transitioning into Clinical Data
Dr. Ellen van der Aar, Clinical Trials Symposium of OARSI 2019
A SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS STUDY WITH INCREASING ORAL DOSES OF GLPG1972 ADMINISTERED DAILY FOR 29 DAYS SHOWS A STRONG BIOMARKER EFFECT IN PATIENTS WITH KNEE AND/OR HIP OA
Favorable human safety, pharmacokinetics and pharmacodynamics of the ADAMTS - 5 inhibitor GLPG1972, a potential new treatment in osteoarthritis
Abstract(s) reprinted from the ACR/ARHP Annual Meeting held November 5-8, 2017. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by Galapagos.